• Mubritinib (TAK 165) in Cancer Biology: Protocols & Innovati

  2026-05-26

  Mubritinib (TAK 165) stands out as a dual-action tool in cancer biology, targeting both HER2 signaling and mitochondrial OXPHOS with precision. This article unpacks advanced workflows, data-driven parameters, and critical troubleshooting tips for leveraging Mubritinib in both AML and HER2-driven cancer research.

• Sulfo-NHS-SS-Biotin: Practical Guide for Cleavable Protein L

  2026-05-26

  Sulfo-NHS-SS-Biotin enables selective, reversible labeling of accessible primary amines on proteins, supporting affinity purification and cell surface protein studies without membrane penetration. It should not be used for intracellular labeling or protocols requiring stable, non-cleavable modification. This reagent's water solubility and disulfide-cleavable spacer streamline workflows where reversible biotinylation is essential.

• IPA-3: Mechanistic Precision and Strategy for Pak1 Pathway R

  2026-05-25

  This thought-leadership article examines the mechanistic underpinnings and translational research opportunities for IPA-3 (1-[(2-hydroxynaphthalen-1-yl)disulfanyl]naphthalen-2-ol), a selective, non-ATP-competitive Pak1 inhibitor. It integrates recent evidence, protocol guidance, and strategic insights to guide researchers in leveraging IPA-3 for high-fidelity kinase assays, disease modeling, and pathway deconvolution.

• Ertapenem Sodium Salt: Strategic Leverage in CREC Research

  2026-05-25

  This article delivers a thought-leadership perspective on deploying Ertapenem (sodium salt) as a precision tool for translational researchers confronting the global challenge of carbapenem-resistant Enterobacter cloacae (CREC). Integrating mechanistic insights, protocol guidance, and current epidemiological findings from Guangdong’s hospitals, it outlines best practices for modeling resistance, validates the criticality of pharmacokinetics, and charts a visionary path for future antibiotic resistance research.

• Dual Metabolic Nanoplatform Boosts Ferroptosis in TNBC Model

  2026-05-24

  This study presents a dual-targeting metal-polyphenol nanoplatform that enhances ferroptotic therapy in triple-negative breast cancer (TNBC) by synchronously inhibiting GPX4 and DHODH and remodeling lipid metabolism. The approach overcomes compensatory resistance, demonstrating robust in vitro and in vivo efficacy, and provides mechanistic insight for advancing ferroptosis-based cancer treatments.

• Indole-3-pyruvic Acid Feedback Regulation in Auxin Biosynthe

  2026-05-23

  This study uncovers a feedback mechanism by which indole-3-pyruvic acid (IPA) regulates the activity of TAA1, coordinating the two-step auxin biosynthesis pathway in plants. These insights advance our understanding of auxin homeostasis, with implications for plant hormone research and metabolic engineering.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Next-Gen Proteasome Inhibitio

  2026-05-22

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) empowers researchers to precisely dissect proteasome function in muscle and fibrosis models, enabling robust, reproducible insights into cell cycle, apoptosis, and osteoclast differentiation. This guide details advanced protocols, troubleshooting strategies, and translational insights from recent muscle aging research.

• Flumequine as a DNA Topoisomerase II Inhibitor: Protocols &

  2026-05-22

  Flumequine’s robust inhibition of DNA topoisomerase II enables high-precision DNA replication and cancer research, offering unique advantages in assay reproducibility and mechanistic clarity. Explore advanced workflows, troubleshooting tips, and data-driven protocol enhancements for reliable application in cell-based and molecular studies.

• Flumequine: DNA Topoisomerase II Inhibitor for Advanced Assa

  2026-05-21

  Flumequine unlocks precise control over DNA topoisomerase II inhibition, enabling advanced DNA replication and repair workflows in cancer and antibiotic resistance research. With optimized DMSO solubility and robust assay performance, it is the preferred research tool for reproducible mechanistic studies.

• Rotenone: Mitochondrial Complex I Inhibitor for Disease Mode

  2026-05-21

  Rotenone uniquely empowers neurodegenerative disease research by enabling precise mitochondrial dysfunction modeling and pathway interrogation. This article details practical workflows, troubleshooting strategies, and new insights from recent gut-brain axis findings—driving reliable results across PD and autophagy pathway studies.

• Lipidated Nanophotosensitizers Suppress Tumor Metastasis via

  2026-05-20

  This study introduces a lipidated nanophotosensitizer capable of tracing and disabling tumor extracellular vesicles (TEVs), thereby inhibiting both tumor growth and metastasis. The approach leverages dual distribution within tumor cells and TEVs to generate reactive oxygen species upon near-infrared irradiation, disrupting prometastatic communication. These findings highlight selective TEV targeting as a promising direction for antimetastatic therapy.

• Nitrocefin in Microbial Resistance Networks: Decoding β-Lact

  2026-05-20

  Explore how Nitrocefin, a premier chromogenic cephalosporin substrate, uniquely illuminates β-lactamase activity within microbial resistance networks. Delve into advanced assay design, reference-driven insights, and practical guidance for multidrug resistance research.

• Targeting eIF4F, AKT1, and EZH2 to Overcome Melanoma Resista

  2026-05-19

  This study demonstrates that simultaneous inhibition of the eIF4F complex, AKT1, and EZH2 significantly enhances anticancer effects in BRAFV600E mutant A375 melanoma cells. The combinatorial approach addresses resistance mechanisms that limit the efficacy of single-agent therapies, providing a rationale for multi-targeted strategies in epigenetic cancer research.

• BMN 673 (Talazoparib): Mechanistic Insights for DNA Repair D

  2026-05-19

  Explore how BMN 673 (Talazoparib) advances DNA repair deficiency targeting with unique mechanistic insights. This article reveals new protocol considerations and practical applications for homologous recombination deficient cancer research.

• Carbohydrate-Decorated Nanoparticles for Macrophage-Targeted

  2026-05-18

  This study demonstrates that biodegradable nanoparticles decorated with carbohydrates such as mannose and dextran markedly enhance the efficiency and specificity of gene delivery to macrophages. These innovations provide a robust foundation for targeted gene therapy in disease models where macrophage modulation is critical.

15623 records 1/1042 page Next 12345 下5页 Last page